A randomized, double-blind, multi-center, placebo-controlled dose ranging study to determine the safety, reactogenicity and immunogenicity of a single oral dose typhoid fever vaccine (Ty800) in healthy adult subjects
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Apr 2008
At a glance
- Drugs Typhoid vaccine Ty800 (Primary)
- Indications Typhoid
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Celldex Therapeutics Inc
- 02 Apr 2008 Results have been reported by AVANT Immunotherapeutics.
- 17 Oct 2007 Status change from recruiting to in progress.
- 08 Aug 2007 New trial record.